TAPDANCE: An automated tool to identify and annotate transposon insertion CISs and associations between CISs from next generation sequence data
© Sarver et al.; licensee BioMed Central Ltd. 2012
Received: 9 December 2011
Accepted: 7 June 2012
Published: 29 June 2012
Next generation sequencing approaches applied to the analyses of transposon insertion junction fragments generated in high throughput forward genetic screens has created the need for clear informatics and statistical approaches to deal with the massive amount of data currently being generated. Previous approaches utilized to 1) map junction fragments within the genome and 2) identify Common Insertion Sites (CISs) within the genome are not practical due to the volume of data generated by current sequencing technologies. Previous approaches applied to this problem also required significant manual annotation.
We describe Transposon Annotation Poisson Distribution Association Network Connectivity Environment (TAPDANCE) software, which automates the identification of CISs within transposon junction fragment insertion data. Starting with barcoded sequence data, the software identifies and trims sequences and maps putative genomic sequence to a reference genome using the bowtie short read mapper. Poisson distribution statistics are then applied to assess and rank genomic regions showing significant enrichment for transposon insertion. Novel methods of counting insertions are used to ensure that the results presented have the expected characteristics of informative CISs. A persistent mySQL database is generated and utilized to keep track of sequences, mappings and common insertion sites. Additionally, associations between phenotypes and CISs are also identified using Fisher’s exact test with multiple testing correction. In a case study using previously published data we show that the TAPDANCE software identifies CISs as previously described, prioritizes them based on p-value, allows holistic visualization of the data within genome browser software and identifies relationships present in the structure of the data.
The TAPDANCE process is fully automated, performs similarly to previous labor intensive approaches, provides consistent results at a wide range of sequence sampling depth, has the capability of handling extremely large datasets, enables meaningful comparison across datasets and enables large scale meta-analyses of junction fragment data. The TAPDANCE software will greatly enhance our ability to analyze these datasets in order to increase our understanding of the genetic basis of cancers.
Forward genetic screens have opened doors to completely novel areas of biological understanding . Starting with fundamental work with yeast, a significant portion of our molecular understanding is built on hypotheses originating from unbiased screens. Recently, forward genetic screens have been used to study the genetics of cancer in vivo, first using murine retroviruses  and more recently using mobile genetic elements or transposons engineered to be active within the murine genome . Transposons are mobilized by the presence of a transposase enzyme, which can be expressed in a tissue specific manner leading to the formation of tissue specific cancers [4, 5]. In the simplest possible conceptual model, tumors may be formed by the disruption of a tumor suppressor gene or activation of an oncogene by a transposon, which then leads to a selective growth advantage for the cell and progeny cells that harbor the insertion. Identification of Common Insertion Sites (CISs) in a significant number of independent tumors strongly implicates genomic regions to be fundamentally involved in tumor formation. Prior work has described methods to identify CISs as well as associations between CISs in datasets [4–9].
Identification of the location of transposon insertion requires obtaining the sequences crossing the junction between the transposon and the authentic genome sequence . Mapping the genomic sequence adjacent to the transposon to a reference genome allows the determination of the specific site of integration. Large numbers of insertion sites can be identified in tumors. Next generation sequencing technology has allowed massive numbers of transposon-genomic junction fragment to be sequenced. The sheer quantity of sequences has introduced unanticipated problems to pipelines designed to identify CISs.
The goal of the TAPDANCE software is to fully automate the analysis of statistically significant CISs using next generation sequencing of insertions from samples where a mobile genetic element has been activated within the genome. In murine forward genetic cancer screens, these CISs represent potential drivers of tumorigenesis. The effort and expense required to validate potential oncogenes and tumor suppressors in human cancer is immense. Yet, the potential benefit to the treatment of these diseases and reducing human suffering cannot be understated. Thus, it is of paramount importance to identify and rank the importance of the driver regions (CISs) of the genome in these datasets. To this end we have developed the software described here, and made it publicly available.
Raw sequence processing and trimming
The generation of PCR products containing the junction fragments between transposon insertion sites and the flanking genomic sequence has been described in detail previously [4–6]. The resulting PCR products are then sequenced utilizing next generation sequencing to generate hundreds of thousands (454 sequencing) or millions (illumina sequencing) of reads 75-100 bp in length. These sequences are loaded at the outset into a relational database and database queries (SQL) are used to identify and remove barcodes denoting the library of origin. Additionally, transposon sequences and linker fragments are trimmed off, leaving only endogenous genomic sequence. In order to speed up the mapping process, identical sequences that are derived from the same library are condensed to a single sequence entry, retaining the total count of observations made.
Sequence mapping to the reference genome
The importance of considering sequence length and mapping directly to the first base following the transposon increases as the total number of sequences examined increases. Since partial linker sequences and unintended ligation products may remain on the 3’-end of full length junction sequences, we developed an iterative mapping process in order to maximize authentic mappings and minimize the potential for mismapping (Figure 2). In the first iteration, full-length sequences are mapped allowing 3 mismatches if their length is >33. In the second iteration sequences that did not map in the first round of mapping had their 3’ ends removed to leave only the first 33 bases. These 33 bases were then mapped allowing 3 mismatches. In the third iteration, sequences that did not map in the second iteration were shortened to 30 bp and combined with shorter sequences before mapping was again attempted allowing 2 mismatches. The procedure was then repeated using sequences of 28 bp (1 mismatch) and 24 bp (0 mismatches).
Mapped regions are exported to a bed file in order to visualize all the “raw” mappings and the strand on which the mapping was observed using genomic browsers such as IGV  or for smaller datasets, the UCSC genome browser .
Elimination of non-clonal insertions
Several artifacts are present in the sequence datasets generated by PCR amplification of insertions. The first artifact is due to remobilization of a clonal transposon insertion into a neighboring TA dinucleotide in a small subset of daughter cells of the original clone. This artifact can be attributed to “local hopping” of the remobilized transposon . In the dataset this artifact presents as a dominant TA with many mapped reads and several neighbouring TA’s with relatively few mapped reads. We hypothesize that these insertions were originally in the dominant TA, and then jumped to the neighbouring TA in a daughter cell. Therefore, these insertions should be grouped with the dominant TA. Another artifact is created when sequencing errors at the beginning of the mapping sequence leads to incorrect mapping to TA positions only a few bases away. This artifact also presents as a dominant TA with a few neighboring TA’s being mapped at a very low frequency. To minimize the impact of counting these non-clonal events as unique events, the raw data counts are binned into 100 bp regions based on the location and orientation of insertion.
Finally, transposon activity is not extinguished as the tumor develops in a forward genetic screen. This means that new insertions will continually occur in daughter cells of the original clone that forms the tumor. Insertions that occur later in the development of a tumor will only occur in a few cells and should be considered passenger mutations. This effect appears in the dataset as mapped insertions that are only counted once or twice, as opposed to clonal insertions that are counted many times by the NGS machine. In order to exclude these low-level passenger insertions, we set a cut-off based on the percentage of the total mappable reads in each tumor. For example, consider a case where 100,000 sequence reads from a single tumor can be uniquely mapped to 1,000 regions in that tumor. In our datasets we find that a subset of the 1,000 regions will be identified by a single sequence read while the remaining regions will be identified by many sequence reads. To set a cut-off we require that a region be identified by, at least, a certain percentage of the total sequence reads that were mapped to that tumor. If we set the cut-off to 1/10,000th that would mean that only the subset of 1,000 regions that were identified by at least 10 reads will be included in CIS analysis. This cut-off eliminates mapped insertions that are only read a few times and probably represent non-clonal insertions. TAPDANCE allows the user to select the cut-off value. Alternatively, the user can choose not to have a cut-off. Based on our analysis of datasets that directly compare the 454 platform with the Illumina GAIIx platform we recommend using no cut-off for 454 data and a cut-off of 1/10,000th for Illumina data.
Project summary files
A summary file is generated for each project that describes the counts for each project, for each directional library, and for each library. The percentage of mappable reads that map to the genome for each run and broken down by library can be obtained from this file. All sequences from a single sequence run are deposited into the SQL database.
Meta-analyses of multiple projects
Each project can be merged with any number of previously existing projects in the database, and files containing all raw mappings and all regional mappings at the thresholds defined in the config.pl file are automatically generated. The software will merge libraries that are identified by the same name, and multiple projects can utilize the same sets of barcodes for different projects without causing confusion, since the informatics model utilizes the library name as a unique identifier.
One of the major bottlenecks in our previous workflows was the combination and reanalysis of datasets that were obtained in separate sets of sequencing runs. To simplify this informatics problem we wrote the software to allow combination of any set of projects to generate a new project or meta-analyses to allow CIS generation from any subset of libraries. In this manner a common set of barcodes can be reused over and over in separate projects and the individual projects can be efficiently analyzed together.
The identification of CISs based on large numbers of sequences from hundreds or thousands of libraries is a nontrivial statistical and informatics challenge. TAPDANCE uses Poisson distribution statistics to calculate CISs. The Poisson distribution determines the probability of observing a given number of events within a region assuming that these events occur in an essentially unbiased manner. In this case the transposon insertions are the events, while the expected number of insertions in a given window is calculated based on the size of the genome and the total number of insertions. The probability estimate is then corrected based on the total number of windows examined (i.e., the total number of insertions) using Bonferroni correction to account for multiple testing. Essentially, the probability of observing a given number of insertions becomes smaller as the genome becomes larger, or the window of interest becomes smaller, or the total number of insertions becomes smaller, or the number of insertions within a given window becomes larger.
e, is the base of the natural logarithm; x, is the actual number of inserts within a window; u, is the number of inserts observed (total) / (genome size /window size).
Each dataset is analyzed multiple times using different window sizes, which generates a list of CISs for each window size analyzed. For each CIS analysis, the window sizes to be used are determined by identifying the maximum window size that will give a corrected p-value < 0.05 (after correcting for multiple testing) with an integer number of insertions by examining window sizes from 10000 bases to 301000 bases in 1000 base steps. If fewer than 2000 insertions or more than 200000 inserts are examined, default window sizes of 12500, 25000,50000,100000, 200000, and 301000 bases are used.
Three methods to count inserts to determine p-value
Donor chromosome considerations
The user is provided with the option of excluding chromosomes from consideration due to the potential for local hopping observed within the donor chromosome (the chromosome where the transposon resides prior to mobilization).
CISs are then automatically annotated based on a user supplied .bed file to provide the names of the genes surrounding the regions of interest. All elements within 20,000 bases are returned to the gene name column. If no elements are present, this field gets filled with the default statement “No results within a 20,000 bp window”.
Every project for which this software has been utilized has required analyses of multiple overlapping and non-overlapping sets of libraries. To facilitate these analyses, the software generates CISs based on a model where the library and the analysis group are defined. Any library within a project can be combined with any other libraries, resulting in the automatic calculation of new combined wig files of raw mapping regions, insertion regions and CISs.
Co-CIS and Pheno-CIS analyses
Valuable biological information can be extracted from the CIS datasets by determining the association between phenotypes and CISs (Pheno-CISs) as well as the associations between individual Cooccurring CISs (Co-CISs). TAPDANCE will automatically generate the associations between the different phenotypes, between phenotypes and CISs, and between separate CISs using Fisher’s Exact test. Fisher’s exact test compares the probability of getting the observed data distribution and all more extreme deviations relative to the null hypothesis, where the proportions between the two groups are random. Multiple testing correction procedures with varying levels of rigor (Bonferroni and Benjamini Hochberg) are then applied separately to each of the three types of associations being tested based on the number of tests conducted. For the determination of association between phenotypes and CISs the total number of tests being calculated can be computed by multiplying the number of phenotypes tested by the number of CISs being tested. For the determination of association between CISs (or between phenotypes) the total number of associations tested can be computed using the formula to calculate the total number of edges and diagonals in a polygon of n sides (total = n(n-1)/2) where n is equal to the number of CISs or the number of phenotypes. It is important to emphasize that examination of association in datasets or parts of datasets with insufficient power may mask significant events due to the necessity to correct for multiple testing. The number of CISs to test for association can be set by the user by defining a maximum p-value for CISs to be considered in association analyses. It is suggested that the user be aware of the power available based on the sample size with regards to the annotations and CISs examined. The default setting is all CISs with a p = value < 10e-5. The phenotypes used for this calculation are all the sets where CIS generation is calculated within a given project as defined by the user.
A number of tests were used to determine that our automated package was performing robustly. Genomic positions were randomly generated and assigned to libraries, with library counts equal to those from real experimental data sets. Analyses of CISs in these random datasets determined that no genomic windows were statistically significant. We further tested authentic mapped mouse sequences obtained from chip-seq input control experiments with library and sequence counts equal to those from real experimental data sets. Somewhat surprisingly, analyses of CISs in these datasets identified several regions with high significance, which were repeatedly found to be present. As these datasets are defined by examining sequences in the absence of any selective pressure, we hypothesize that these are regions that are present in high copy number within the murine genome but they are mistakenly annotated as a single copy in the genome build. This hypothesis is supported by other groups . As these regions are also observed in many of the screens we have conducted, we believe that these regions should not be considered as drivers of tumorigenesis. We also found another artifact specific to transposon screens that contain endogenous murine sequence within the transposon. Due to local hopping within the original donor concatamer, the LM-PCR protocol will amplify these internal jumps and they will map to the murine genome. For example, part of the EN2 murine gene sequence is included in the T2/Onc transposon. In SB screens using this transposon, insertions mapping to EN2 are excluded because of this artifact. All known artifact regions, such as these, are labeled with the string 'BAD' in the annotation bed file and are not reported by the software. The excluded regions are included as Additional file 1: Table S1.
To compare the full functionality of TAPDANCE with previous methods we reanalyzed the sequences obtained for previously published colon cancer and liver cancer screens [3, 4]. Running the process using TAPDANCE takes a fraction of the time of the original process. These datasets were generated using the Roche 454 GS/Flex platform. A representative summary of the 4 required input files is provided as Additional file 1: Table S7. Summary statistics are presented for the dataset as a whole (Additional file 1: Table S8A) as well as broken down by barcode (Additional file 1: Table S8B) and finally by library (Additional file 1: Table S8C).
The CIS thresholds automatically calculated via iterative poisson distribution statistical analyses are very similar to those defined by Monte Carlos simulation and are calculated almost instantaneously (Additional file 1: Table S2).
The CIS list is generated as a spreadsheet that contains the chromosome, start and end address of the CIS region, the 3 associated p-values (insert, library, and region), the libraries that are included, and the annotation. Additionally the total count of inserts that are capable of driving insertions on the positive strand are provided for each CIS. This number can be combined with the total number of insertions to determine whether a specific gene is potentially being overexpressed or is being disrupted due to the orientation of transposon insertion.
To further demonstrate the co-CIS capability of the software we analyzed an insert dataset derived from retroviral insertions obtained from the RTCGD . This dataset composed of ~6700 mapped insertions derived from ~1600 tumor libraries was analyzed for CIS using the TAPDANCE methodology. The results are consistent with previously generated results (Additional file 1: Table S9) and co-CIS were calculated between CIS with a region p-value < 0.00001. The top hits obtained by alternative formulations of co-occurring insertion event analyses [7, 9] in this dataset were also obtained by TAPDANCE coCIS analyses (Additional file 1: Table S10).
Finally, we compared our CIS calculation method directly with the modified Gaussian kernel convolution framework  using a pancreatic cancer dataset recently published . Our method was able to find and score 18 of the top 20 regions within the top 31 CIS (Additional file 1: Table S11). All top 20 CIS were scored within the top 50 CIS by TAPDANCE. The majority of the differences can be attributed to the different methods of ranking used in the final sorts. It should also be noted that the sequence analyses and genome mappings were done independently, indicating that the full TAPDANCE pipeline is showing similar results to the modified Gaussian kernel convolution method.
Previously, multiple steps in CIS generation sequence cleaning, mapping to the genome, CIS calling, and association needed to be carried out separately in a non-automated fashion. In this work we present a fully automated rationally derived method for complete analyses and make it publicly available. Previously, Monte Carlo simulation based on the actual TA density within the genome as well as the number of inserts on each chromosome was used to estimate the number of inserts necessary to be called a CIS within a given window. Our method, utilizing the Poisson distribution based calculation directly provides similar results (Additional file 1: Table S2) in a far less computationally intense and fully automated fashion. In practice, window size thresholds and significance cutoffs are remarkably similar to Monte Carlo simulation based on TA density on a chromosome by chromosome basis and calculated in a fraction of the time. Additionally, P-values are generated for each CIS, which is not possible using the Monte Carlo method as previously implemented. The incorporation of multiple schemes of counting of inserts for use within the p-value calculation based on 1) total number of inserts within a window; 2) based on the total number of libraries; 3) the total number of unique insert regions allows for the selection of CISs with “ideal” tumor driver characteristics to be ranked higher than CISs with less ideal characteristics.
We show that the potential for incorrect mapping exists with short sequences, and resolve this by requiring input sequences to be of sufficient length such that no sequences will be mapped by random chance. Additionally we have shown that 1) our empirically derived statistical model for CIS calling behaves adequately using random positional/library data and 2) real bias exists in murine sequencing data that needs to be taken into account in the analyses of CISs.
This methodology is robust, statistically conservative and efficient. The results generated are consistent with previous workflows, both in the statistical thresholds identified as well as the CIS list membership. This method has a number of advantages. It runs much faster, and is capable of running the volume of data currently being generated via current NGS techniques. Similar results are obtained, independent of sequencing depth once a basic sampling threshold is reached. Using this system we are able to obtain similar CIS results from datasets that are sequenced separately using 454 (~1000’s of sequences per library) and Illumina (~100,000’s of sequences per library). We have utilized this software in the analyses of ~20 different forward genetic screens using both 454 and Illumina based sequencing approaches.
Widespread incorporation of this software will allow meaningful meta-analyses of transposon based genetic screens. We also note that the software can be readily configured to identify CISs and associations from any organism.
The command line version of TAPDANCE requires the user to have Bowtie , PERL DBI and R software installed. The command line version also requires access to a read /write mysql account.
We thank Keiko Akagi for providing help with accessing data stored within the RTGCD database. We thank the Minnesota Supercomputing Institute for providing access to computational resources.
- St Johnston D: The art and design of genetic screens: Drosophila melanogaster. Nat. Rev. Genet 2002, 3: 176–188. 10.1038/nrg751View ArticlePubMed
- Uren AG, Kool J, Berns A, van Lohuizen M: Retroviral insertional mutagenesis: past, present and future. Oncogene 2005, 24: 7656–7672. 10.1038/sj.onc.1209043View ArticlePubMed
- Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA: Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005, 436: 272–276. 10.1038/nature03681View ArticlePubMed
- Starr TK, Allaei R, Silverstein KAT, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O’Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA: A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009, 323: 1747–1750. 10.1126/science.1163040PubMed CentralView ArticlePubMed
- Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, Silverstein KAT, Sarver A, Starr TK, Akagi K, Tessarollo L, Collier LS, Powers S, Lowe SW, Jenkins NA, Copeland NG, Llovet JM, Largaespada DA: A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 2009, 27: 264–274. 10.1038/nbt.1526PubMed CentralView ArticlePubMed
- de Ridder J, Uren A, Kool J, Reinders M, Wessels L: Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol. 2006, 2(12):e166. 10.1371/journal.pcbi.0020166PubMed CentralView ArticlePubMed
- de Ridder J, Kool J, Uren A, Bot J, Wessels L, Reinders M: Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. Bioinformatics. 2007, 23(13):i133–41. 10.1093/bioinformatics/btm202View ArticlePubMed
- Brett BT, Berquam-Vrieze KE, Nannapaneni K, Huang J, Scheetz TE, Dupuy AJ: Novel molecular and computational methods improve the accuracy of insertion site analysis in Sleeping Beauty-induced tumors. PLoS One. 2011, 6(9):e24668. 10.1371/journal.pone.0024668PubMed CentralView ArticlePubMed
- Bergemann TL, Starr TK, Yu H, Steinbach M, Erdmann J, Chen Y, Cormier RT, Largaespada DA, Silverstein KA: New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens. Nucleic Acids Res 2012.
- Largaespada DA, Collier LS: Transposon-mediated mutagenesis in somatic cells: identification of transposon-genomic DNA junctions. Methods Mol. Biol. 2008, 435: 95–108. 10.1007/978-1-59745-232-8_7PubMed CentralView ArticlePubMed
- Langmead B, Trapnell C, Pop M, Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009, 10: R25. 10.1186/gb-2009-10-3-r25PubMed CentralView ArticlePubMed
- Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP: Integrative genomics viewer. Nat. Biotechnol. 2011, 29: 24–26. 10.1038/nbt.1754PubMed CentralView ArticlePubMed
- Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, Roskin KM, Schwartz M, Sugnet CW, Thomas DJ, Weber RJ, Haussler D, Kent WJ: The UCSC Genome Browser Database. Nucleic Acids Res. 2003, 31: 51–54. 10.1093/nar/gkg129PubMed CentralView ArticlePubMed
- Liang Q, Kong J, Stalker J, Bradley A: Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons. Genesis 2009, 47: 404–408. 10.1002/dvg.20508View ArticlePubMed
- Quinlan AR, Clark RA, Sokolova S, Leibowitz ML, Zhang Y, Hurles ME, Mell JC, Hall IM: Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome. Genome Res. 2010, 20: 623–635. 10.1101/gr.102970.109PubMed CentralView ArticlePubMed
- Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG: RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004, 32(Database issue):D523–7. 14681473 14681473PubMed CentralView ArticlePubMed
- Pérez-Mancera PA, Rust AG, van der Weyden L, Gl K, Al L, Sarver AL, Silverstein KAT, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Goggins M, Hruban RH, Biankin AV, Grimmond SM, Wessels LFA, Wood10 SA, Iacobuzio-Donahue4 CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson1 DA: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486(7402):266–270.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.